The Central Drugs Standard Control Organization vide its notification dated 29th April 2021 has requested all the manufacturers/importers to increase manufacturing/import of in-vitro diagnostic testing reagents/kits to maximum capacity and at fast pace in light of increasing cases of covid-19 positive cases.
The Patients who are COVID-19 positive may require testing for inflammatory markers such as IL-6, D-Dimer and CRP.The result of these important tests directly dictate the management of COVID-19 patients by the physicians to take further timely decisions.
Further the manufacturers shall submit information about the reagents/kits manufactured, current stock and the capacity to manufacture and proposed capacity to CDSCO.
